Loading…
Entera Bio Ltd. is projected to rise to $1.80 by 2027, a +9% move from its current price of $1.66. ENTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.59 | $1.66 | $1.72 | +0.03% |
| Jul 13 | $1.56 | $1.66 | $1.75 | +0.06% |
| Jul 14 | $1.54 | $1.66 | $1.78 | +0.08% |
| Jul 15 | $1.53 | $1.66 | $1.80 | +0.11% |
| Jul 16 | $1.51 | $1.66 | $1.82 | +0.14% |
| Jul 17 | $1.50 | $1.66 | $1.83 | +0.17% |
| Jul 18 | $1.49 | $1.66 | $1.85 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.49 | $1.66 | $1.85 | +0.19% |
| Week 2 | $1.43 | $1.66 | $1.93 | +0.39% |
| Week 3 | $1.38 | $1.66 | $2.01 | +0.58% |
| Week 4 | $1.34 | $1.67 | $2.07 | +0.78% |
| Week 5 | $1.31 | $1.67 | $2.13 | +0.97% |
| Week 6 | $1.29 | $1.67 | $2.18 | +1.17% |
| Week 7 | $1.26 | $1.68 | $2.23 | +1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Entera Bio Ltd. is a clinical stage company that develops oral peptides and protein replacement therapies in Israel and internationally. Its programs include EB613, EB612, EB618, and GLP-2, with EB613 described as an oral teriparatide that completed the Phase II clinical trial for the treatment of osteoporosis and Phase I for the treatment of stress fractures.
EB612 is in Phase I for hypoparathyroidism; EB618 is a GLP-1/glucagon dual agonist peptide in Phase I for obesity, metabolic, and fibrotic disorders; and GLP-2 is in Phase I for short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption.
The company has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. Entera Bio was incorporated in 2009 and is based in Jerusalem, Israel.
Entera Bio Ltd. (ENTX) is currently trading at $1.63 with a market cap of $80.34M and a rank of 4309.
The 30-day technical picture is bullish, with RSI14 at 70 and the price near resistance at $1.63. The 50-day moving average sits at $1.25, suggesting near-term momentum alongside the price action.
The 200-day moving average is $1.69, with a support level at $1.16 and a resistance at $1.63. The long-range forecast shows averages climbing over time, starting with 2026 at $1.63 and advancing to $2.10 in 2030, $5.76 in 2040, and $9.49 in 2050, accompanied by rising rois and bullish sentiment from 2030 onward.
A major floor 44.5% below — a decisive break under it would weaken the trend.
The nearest floor, 29.9% below — buyers have tended to step in here.
The nearest ceiling, 6.9% above — a clean break opens room to run.
A major ceiling 29.2% above — clearing it would confirm fresh momentum.
Key ENTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.68 | Sell | $1.67 | Sell |
| MA 10 | $1.68 | Sell | $1.64 | Buy |
| MA 20 | $1.50 | Buy | $1.54 | Buy |
| MA 50 | $1.34 | Buy | $1.41 | Buy |
| MA 100 | $1.30 | Buy | $1.41 | Buy |
| MA 200 | $1.68 | Sell | $1.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.23 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 54.23 | Neutral |
| Williams %R (14) | -35.94 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 6.77 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 64.06 | Neutral |
| TRIX (15) | 1.20 | Buy |
| Awesome (5,34) | 0.29 | Buy |
| Ultimate (7,14,28) | 46.36 | Neutral |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 1.68 | Sell |
| ADX (14) | 22.90 | Buy |
| ATR (14) | 0.05 | Info |
The 30-day picture indicates bullish momentum with RSI14 at 70. Price is trading around the near-term resistance of $1.63, while the 50-day SMA is $1.25 and the 200-day SMA is $1.69.
Support is shown at $1.16, with resistance at $1.63. The 30-day price range spans from a low of $1.18 to a high of $2.24, highlighting a contained but upward-trending session.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.00 | $1.66 | $2.21 | 0% | Neutral | |
| $1.37 | $1.80 | $2.54 | +9% | Neutral | |
| $1.30 | $1.79 | $2.66 | +8% | Neutral | |
| $1.43 | $2.05 | $3.17 | +24% | Bullish | |
| $1.62 | $2.39 | $3.81 | +44% | Bullish | |
| $2.08 | $3.16 | $5.21 | +91% | Bullish | |
| $2.32 | $3.63 | $6.13 | +119% | Bullish | |
| $2.20 | $3.54 | $6.11 | +114% | Bullish | |
| $2.24 | $3.70 | $6.52 | +124% | Bullish | |
| $2.26 | $3.82 | $6.87 | +131% | Bullish | |
| $3.47 | $6.61 | $12.88 | +299% | Bullish | |
| $5.08 | $11.29 | $24.68 | +582% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.00 | $1.66 | $1.96 | +0.00% |
| August 2026 | $1.37 | $1.64 | $2.03 | -1.10% |
| September 2026 | $1.40 | $1.70 | $2.14 | +3.69% |
| October 2026 | $1.37 | $1.67 | $2.13 | -1.72% |
| November 2026 | $1.32 | $1.63 | $2.10 | -2.49% |
| December 2026 | $1.37 | $1.70 | $2.21 | +4.31% |
Click any year to see its month-by-month ENTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ENTX to range from $1.00 to $2.21 through 2026. The $1.66 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ENTX price prediction for 2027 points to an average of $1.80 (low $1.37, high $2.54) — a potential gain of +9% on today's $1.66. A consolidation phase looks the most probable path here.
In 2028, ENTX is projected to trade between $1.30 and $2.66, averaging $1.79 — a potential gain of +8% from today's $1.66. That is 0% versus the projected 2027 average. Price action looks broadly range-bound.
Entera Bio Ltd.'s 2029 outlook centres on $2.05, within a $1.43 to $3.17 range. That is up +14% on the projected 2028 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ENTX could reach as high as $3.81, with a base case around $2.39 and support toward $1.62 — roughly +44% from $1.66. Momentum favours further upside here.
Expect ENTX to range from $2.08 to $5.21 through 2031. The $3.16 average target implies a +91% move from current prices. That is up +33% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ENTX price prediction for 2032 points to an average of $3.63 (low $2.32, high $6.13) — a potential gain of +119% on today's $1.66. Momentum favours further upside here.
In 2033, ENTX is projected to trade between $2.20 and $6.11, averaging $3.54 — a potential gain of +114% from today's $1.66. That is -2% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Entera Bio Ltd.'s 2034 outlook centres on $3.70, within a $2.24 to $6.52 range. That is up +4% on the projected 2033 average. That marks a +124% change versus current levels. Momentum favours further upside here.
By 2035, ENTX could reach as high as $6.87, with a base case around $3.82 and support toward $2.26 — roughly +131% from $1.66. Buyers look set to stay in control over this stretch.
Expect ENTX to range from $3.47 to $12.88 through 2040. The $6.61 average target implies a +299% move from current prices. That is up +73% on the projected 2035 average. Momentum favours further upside here.
The ENTX price prediction for 2050 points to an average of $11.29 (low $5.08, high $24.68) — a potential gain of +582% on today's $1.66. Buyers look set to stay in control over this stretch.
Investing $1,000 in ENTX today (≈ 604.229607 ENTX) could be worth
$6,824.71
+$5,824.71 (+582%) by 2050 · US Dollar
Based on the average projected ENTX price of $11.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENTXwould be worth at today's price.
$1,000 invested in ENTX on Jul 10, 2025 (≈ 543.478251 ENTX) would be worth
$899.46
-$100.54 (-10.1%) today · 0.90× · US Dollar
Based on a ENTX entry price of $1.84 vs. today's $1.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.66 | $996.99 | -0.3% |
| 1 month ago | $1.17 | $1,414.53 | +41.5% |
| 3 months ago | $1.15 | $1,439.13 | +43.9% |
| 6 months ago | $1.57 | $1,054.14 | +5.4% |
| 1 year ago | $1.84 | $899.46 | -10.1% |
| All time (5.0y) ago | $5.75 | $287.83 | -71.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENTX forecast.
Our base-case forecast reaches $3.30 around 2032.
Implied market cap at $3.30: $162.66M
The multi-year forecast depicts a path of steadily rising averages, from a 2026 avg of $1.63 to a 2050 avg of $9.49.
Key year-by-year milestones show 2030 with an avg of $2.10 and a 2030 ROI of 28.6%, followed by 2031 avg $2.90 and 78.1% ROI, then 2032 avg $3.39 with 107.7% ROI, and 2033 avg $3.07 with 88.2% ROI. The growth continues through 2034 at $3.28 (101.3% ROI) and 2035 at $3.41 (109.2% ROI). By 2040 the avg is $5.76 with a 253.2% ROI, and by 2050 the avg reaches $9.49 with a 482.3% ROI.
Sentiment shifts from NEUTRAL in 2026–2029 to BULLISH from 2030 onward. These figures are estimates and not guarantees, reflecting potential upside under the given assumptions.
Tap a question to reveal the answer.
In 2030, the avg price is $2.10, with a min of $1.34 and a max of $3.53; ROI is 28.6%, and sentiment is BULLISH.
The year-by-year forecast shows mixed near term, with 2026 showing 0% ROI and NEUTRAL sentiment, followed by 3.1% in 2027 and -1.4% in 2028, then 15.3% in 2029. From 2030 onward, the outlook is bullish, with higher averages and ROIs up to 482.3% by 2050. These are estimates, not guarantees.
Yes. In 2031, max is $5.05 with avg $2.90; in 2032, max is $6.07, allowing the price to exceed $5 in 2031–2032.
Current price is $1.63 and market cap is $80.34M.
The 30-day range is $1.18 to $2.24.
Entera Bio Ltd. Community Discussion
0Share your Entera Bio Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.